Dear Dr. Renukaprasad A R,  About 1% of the Indian population suffers from heart failure (HF), with an estimated mortality of 0.1-0.16 million individuals annually. It is estimated that up to 46% of type 2 diabetes mellitus patients will develop some form of CVD during their lifetime. ELECSYS NTproBNP is recognized as a gold standard biomarker in HF and is recommended by international HF guidelines. Serial NTproBNP measurements provide prognostic information on mortality and hospitalization for HF. Read this article to understand the application of NTproBNP for cardiac risk assessment in T2DM patients. | .png)
No comments:
Post a Comment